financetom
Business
financetom
/
Business
/
Why Dollar Tree Shares Are Falling Thursday (CORRECTED)
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Dollar Tree Shares Are Falling Thursday (CORRECTED)
Aug 31, 2024 8:08 PM

Editor’s note: This story has been updated to correct a headline error that erroneously attributed a quote from Dollar General’s CEO to the Dollar Tree ( DLTR ) CEO and wording in the story that conflated Dollar Tree ( DLTR ) and Dollar General ( DG ).

Dollar Tree, Inc. ( DLTR ) shares were down nearly 10% Thursday following a disappointing earnings report from competitor Dollar General Corp ( DG ) .

Earlier this week, Wells Fargo analyst Edward Kelly maintained Dollar Tree ( DLTR ) with an Overweight rating. He also lowered the price target from $160 to $130.

Dollar Tree ( DLTR ) shares are moving in sympathy with its top peer Dollar General ( DG )‘s sluggish results. Dollar General ( DG ) CEO Todd Vasos, cautioned about softer sales trends in the broader sector.

Core customers feel financially constrained, he says.

The retail behemoth reported second-quarter earnings per share of $1.70 Thursday, missing the analyst consensus of $1.78. Quarterly sales of $10.21 billion (+4.2% year over year) missed the Street view of $10.368 billion.

Also Read: Dollar General ( DG ) Q2 Earnings: Earnings Miss, Slashed Outlook And Shrinking Margins

“We are not satisfied with our financial results, including top line results below our expectations for the quarter,” Vasos said.

Vasos indicated that, in response to the changing retail and consumer environment, the company is taking decisive steps to improve its value and convenience offerings, as well as the in-store experience for both associates and customers.

“Dollar General has a long history of serving customers in a variety of macroeconomic environments, and we believe the actions we are taking will allow us to further strengthen our position and build on our Back to Basics progress, as we seek to deliver sustainable growth and long-term shareholder value,” Vasos added.

Dollar General ( DG ) has revised its fiscal year 2024 outlook, lowering its EPS forecast from a range of $6.80 to $7.55 to a new range of $5.50 to $6.20, compared to the $7.12 estimate.

The company also reduced its revenue forecast from $41.01 billion to $41.28 billion to a revised range of $40.51 billion to $40.74 billion, against the $41.02 billion estimate.

Dollar General ( DG ) continues to expect 2,435 real estate projects. That includes 730 new store openings, 1,620 remodels, and 85 store relocations in fiscal year in 2024.

Price Action: Dollar Tree ( DLTR ) shares are trading lower by 9.64% to $85.35 at last check Thursday. According to Benzinga Pro, the stock has lost over 23% in the past year.

Read Next:

Wall Street On Track For Relief Rally With Nvidia Earnings In Rearview Mirror: Strategist Says Near-Term Market Trajectory May Not Hinge On Presidential Election But This

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Replimune Says FDA Accepted its Biologics License Application  Resubmission for Treatment of Advanced Melanoma
Replimune Says FDA Accepted its Biologics License Application Resubmission for Treatment of Advanced Melanoma
Oct 20, 2025
07:35 AM EDT, 10/20/2025 (MT Newswires) -- Replimune Group ( REPL ) said Monday the US Food and Drug Administration has accepted the resubmission of the Biologics License Application for its lead product candidate, RP1, in combination with nivolumab for the treatment of advanced melanoma, a type of skin cancer, in patients who progress on an anti-PD-1 containing regimen. The...
Sintx Technologies Says Foot, Ankle Implant System Gets FDA Clearance; Shares Up Pre-Bell
Sintx Technologies Says Foot, Ankle Implant System Gets FDA Clearance; Shares Up Pre-Bell
Oct 20, 2025
07:35 AM EDT, 10/20/2025 (MT Newswires) -- Sintx Technologies ( SINT ) said Monday its Sinaptic foot and ankle osteotomy wedge system received 510(k) clearance from the US Food and Drug Administration. The implant system combines silicon nitride biomaterial with surgeon-informed implant designs for foot and ankle reconstructive surgery. Sintx ( SINT ) said it plans a US commercial launch...
Form 8.3 - ME Group International plc
Form 8.3 - ME Group International plc
Oct 20, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Montanaro Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Merck Begins Construction on $3 Billion Manufacturing Facility in Virginia
Merck Begins Construction on $3 Billion Manufacturing Facility in Virginia
Oct 20, 2025
07:32 AM EDT, 10/20/2025 (MT Newswires) -- Merck ( MRK ) said Monday it has started construction on a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. The drugmaker said the project is part of a broader plan to invest over $70 billion starting in 2025 to expand domestic manufacturing and R&D capabilities. The company said the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved